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 Influence of API-excipients interaction of polymorphism 
 Polymorph thermal transformation of monitoring by MIR/MCR-ALS approach 






The assessment of polymorphism is a problematical issue for regulatory agencies, 
because variations among crystalline forms of active pharmaceutical ingredient (API) can lead 
to changes in the efficacy and safety of formulated product. Such conversions are very hard to 
be detected, thus, the development of techniques for the identification, characterization and 
quantification of polymorphs results essential in all stages of the manufacturing process.  
The presence of excipients in formulated products may change the crystal stability of an 
API, by catalyzing a polymorphic transformation or stabilizing the less stable form. As paradox, 
all suitable analytical techniques (spectroscopies, thermal analysis, NMR and DRX, and others) 
for polymorphic analysis are affected by excipients. A deep understanding of the 
polymorphism-excipient relationship is in full accordance with Quality by Design (QbD) 
paradigm, the systematic approach focused in quality building into a product based in the full 













In this work, a novel approach based on thermal stress, MIR monitoring, multivariate 
curve resolution with alternating least squares (MCR-ALS) and kinetic analysis was developed 
and applied to monitor polymorphism behavior of model API in formulated products. 
Commercial tablets, physical mixtures and commercial API, were processed and analyzed 
under the proposed approach. Commercial tablets of MFA revealed a fast conversion to Form 
II, contrasting to the behavior of the pure API. Physical mixtures showed similar behavior to 
commercial tablets, thus reduction in transformation times was related to MFA-excipients 
physical interaction, even at surface level. Calorimetric studies support the conclusion obtained.   
The developed approach could be extended to others APIs and other stress sources 
(humidity, solvents, mechanical forces and its combinations), being a valuable tool for QbD 
environment.  
 
Abbreviations: API, active pharmaceutical ingredient; ATR, attenuated total reflectance 
accessory; BCS, biopharmaceutics classification system; COM, commercial bulk product; 
EXC, excipients; COMEX, physical mixtures of COM and EXC; DSC, differential scanning 
calorimetry; MCR-ALS, multivariate curve resolution with alternating least squares; MFA, 
Mefenamic Acid; MIR, middle infrared spectroscopy; NIR, near infrared spectroscopy; PAT, 
Process Analytical Technology; QbD, Quality by Design; TAB1, tablets sectioned 
longitudinally; TAB2, tablets reduced to powder. 
 




The polymorphism of active pharmaceutical ingredients (APIs) is a major concern for 
pharmaceutical industry due to its influence on physical and chemical properties of 
pharmaceutical powders [1]. Changes in crystalline form can also lead to variations in efficacy 
and safety of formulated product due to polymorphic systems with intrinsically different lattice 
energies manifest dissimilar enthalpies of fusion and solubilities [2]. 
Thus, polymorphism results in APIs that exhibit differential properties such as apparent 













of pharmaceutical form and its bioavailability [3,4]. Hence, it is crucial to identify the different 
polymorphs, to determine their stability, and to assess the effect of processing conditions on 
polymorphic conversions [5]. 
Thermal or mechanical energy given from drying, milling, or compaction may accelerate 
the transition to the stable polymorph of the API. Generally, solid-state phase transitions are 
influenced by crystalline defects, impurities, particle size, APIs distribution, excipients, and 
environment factors such temperature, pressure and relative humidity (RH) [6]. In a Quality by 
design (QbD) environment, determination of physical or chemical interactions between APIs 
and excipients is crucial [7,8], in order to build the understanding of the product and process 
along a knowledge of the risks involved in manufacturing and how best to mitigate those risks.  
The process of polymorph transformation can be inhibited or catalyzed by components 
of the formulate product. Excipients may facilitate conversion to the amorphous drug, which 
may subsequently compromise chemical stability [9,10], such is the case of immediate release 
tablets containing a prototype API [11]. Although, the API demonstrate to be chemically stable 
and compatible with the excipients; a potency loss was observed over accelerate stability tests 
(6 months, 40ºC/75RH) due to rapid API degradation. Authors revealed that during wet 
granulation anhydrous API converted to the monohydrate API and, after the drying operations 
in the presence of excipients, the monohydrate transformed to the amorphous form. The 
excipients inhibited the fast re-crystallization of amorphous API, resulting in an increased its 
content. The amorphous form was responsible for the poor stability of the wet granulated 














Scheme 1. Influence of excipients on the chemical stability of immediate release tablets 
containing a prototype API [11]. 
Only a few analytical techniques are able to detect polymorphic/pseudo-polymorphic 
transformations as descripted above [11]. In such scenario, the quantitative analysis is even 
more difficult to perform and it gets worse when the excipients interferer [6]. 
Calorimetric methods and vibrational spectroscopies are the more widespread techniques 
for polymorphs characterization; however, solid state nuclear magnetic resonance (ssNMR) and 
powder X-ray diffraction (pXRD) remain as gold standard [12]. Nevertheless, pXRD and 
ssNMR, are of difficult implementation in routinely quality control due to the high cost of the 
equipment. Additionally, pXRD had two major issues, the need of high theory knowledge of 
system for Rietveld calculations [13] and crystalline excipients may affect diffractogram 
acquisition.  
Differential thermal gravimetry (DTG), differential thermal analysis (DTA) and 
differential scanning calorimetry (DSC), are able to sense transformations (fusions, 
conversions, recrystallization, desolvation and others). Nevertheless, they do not provide 
information about identity of species involved such conversions, instead this transformations 
are “the key features” of the polymorphs [14]. The thermosgrams may be interfered by the 
excipient transformation (i.e melting point) or excipient-API interactions (ie. in the cases of 
eutectic mixtures). 
Vibrational spectroscopies [Raman, near (NIR) and middle infrared (MIR) 
spectroscopies], are widespread techniques used for the polymorphism analysis, since they are 
sensitive to minor variations in conformation of organic molecules, such those involved in 
lattice structure changes [15]. However, the high number of signals, sometimes poorly resolved, 
present in their spectra make impossible quantitative analysis of polymorph mixtures using 
naked eye. Furthermore, the presence of excipients does not allow to detect any polymorph 
change even at qualitative level. Nevertheless, these methodologies do not require solvent, 
gases or another consumable, operate fast and without sample destruction, making them the 
first choice for routinely quality control and even as process analytical technology (PAT) tool. 
In such way, several groups developed approaches to identify or quantitate polymorphs 
in drug substance and drug products using vibrational spectroscopies aided by chemometrics. 
Raman spectroscopy was coupled to PLS algorithm to analyze the main polymorph in 













mebendazole and cimetidine tablets to polymorph assignment. There, PCA allow data 
compression and visualization, and further statistical analysis using Mahalanobis distance 
[17,18]. Additionally, NIR spectroscopy was the only vibrational spectroscopy able to 
successfully predict polymorphic content in commercial tablets of Mefenamic acid, using the 
obtained polymorphic content to predict the solubility performance [19]. 
Dynamic process, such a polymorphic (and pseudo polymorphic) inter-conversion were 
also studied using chemometrics and vibrational spectroscopies. This is the case of a 
monohydrate of cimetidine in which become selectively to form A under thermal treatment. 
Such transformation was unveiled analyzing MIR data by multivariate curve resolution with 
alternating least squares (MCR-ALS) algorithm, since it has no resolution using thermal 
analysis (DSC or DTG) [20]. In the same way, the inter-conversion of two crystalline forms of 
nimodipine was resolved by MCR-ALS and MIR spectroscopy [21]. However, the last 
approaches were only applied to drug substance and not to formulated products. 
Hence, the scope of this work is to reveal the influence of excipient mixture in a plausible 
polymorphic transformation.  A novel approach based on thermal stress, MIR monitoring, 
MCR-ALS and kinetic analysis was developed for polymorphism monitoring in formulated 
products. The present work deals with monitoring of Mefenamic Acid (MFA) polymorphism 
in commercial tablets. 
MFA is a potent inhibitor of prostaglandin synthesis closely related to inflammatory 
processes [22]. MFA polymorphic forms show enantiotropic relationship, a conversion of Form 
I to Form II (Figure 1) occurs above 180 °C [23]. Hence, conversion to Form II (metastable 
form) may compromise stability of the pharmaceutical product and may alter the safety and 
efficacy of the API.  
The phenomena of crystalline conversion of MFA in formulated product were studied 
analyzing physical mixtures and commercial tablets to the influence of the 
excipients/formulation process. The application of MIR spectroscopy coupled to MCR-ALS 
result in a new alternative in the monitoring of drug-excipient interactions that can be very 
useful in development stages of new solid pharmaceutical forms following, the guidelines QbD. 
As far we know, no approaches have been previously reported in the literature that monitoring 















Figure 1. Conformational changes in MFA between Form I and Form II. 




Calorimetric determinations were performed in a Shimadzu 60 differential scanning 
calorimeter (Shimadzu Corp., Kyoto, Japan), operating under a Nitrogen atmosphere at a 
constant flow of 50 mL by min−1. The samples (~5 mg) were placed in closed aluminum pans 
with a pinhole to equilibrate pressures, and heated at a rate of 5 C min-1 between 30 and 300 
ºC. An empty aluminum pan was used as a reference. 
MIR spectra were acquired in a Shimadzu Prestige 21 spectrophotometer (Shimadzu 
Corp., Kyoto, Japan) in 3800–600 cm−1 range with a resolution of 4 cm-1. Attenuated total 
reflectance (ATR) experiments were carried out with a diamond-based ATR accessory 
(GladiATR, Pike Technologies, Madison, USA).  The samples were measured by triplicate. 
The particle size of the solids samples was standardized by sieving, employing a Zonytest 
EJR 2000 fine mesh vertical vibratory sieving tower (Rey & Ronzoni, Buenos Aires, 
Argentina), operating at 1200 rpm. In all cases, the 100–140 mesh fractions were collected. 
The physical mixtures of solids were homogenized using a Z-mixer powered by rotatory 
platform with an electronic control of speed Precytec AT-15D, at 30 rpm.  
The thermal treatment of the samples was carried out with a hotplate stirrer Talboys-all 
(Troemner, Thorofare, USA) digital controlled and fitted with an RTD temperature probe 















The MFA pharmaceutical grade (COM) was gently donate by Laboratorios ELEA. 
Excipients used (methylcellulose, cornstarch, silicon dioxide, microcrystalline cellulose, 
sodium croscarmellose, sodium lauryl sulfate and magnesium stearate) were of pharmaceutical 
grade and were acquired from “Droguería Saporiti” (Buenos Aires, Argentina). Commercial 
tablets containing 500 mg of MFA (average total weight: 713.91 mg) were purchased from a 
local pharmacy. 
All other chemicals were of analytical grade and were used as received. During the 
experiments, API and its forms were kept in a desiccator and protected from light. 
2.3. MFA pure forms 
 
MFA pure forms (Form I and Form II) used as references were prepared according to 
recently reported procedures [19]. Identity of purity of the forms were confirmed by optical 
microscopy, MIR and NIR spectroscopy, melting point determination and DSC.  
2.4. Sample preparation  
2.4.1. MFA drug substance 
Before experiments and analysis, COM samples were previously sieved, collecting the 
fractions comprised between 100-140 mesh, in order to homogenize the particle size. Then, 
obtained fractions were mechanical mixed.  
 
 
2.4.2. Physical mixtures 
 
Physical mixtures (COMEX) containing COM and excipient matrix (EXC) in proportions 
equivalent to commercial product were prepared to simulate the tablet environment. 
EXC was prepared by weighting and mixing the following components: methylcellulose 
(9.55 g), corn starch (95.53 g), silicon dioxide (2.00 g), microcrystalline cellulose (96.61 g), 
sodium croscarmellose (3.52 g), sodium lauryl sulfate (2.89 g) and magnesium stearate (2.00 
g). Particle size of excipients was previously homogenized by sieving, collecting the fractions 
comprised between 100-140 mesh. Subsequently, the mechanical mixing of the components 













2.4.3. Commercial samples 
 
 Commercial samples were divided in two sets, in set 1 (TAB1) tablets were longitudinally 
sectioned to maintain the original distribution of the components in the pharmaceutical form 
during the test. In set 2 (TAB2), tablets were gently reduced to powder and sieved to obtain 
homogeneous samples, 100-140 mesh fractions were finally used for the analysis.  
2.5. Thermal treatment 
 For each sample, six aliquots of approximately 250 mg were placed in hermetical glass 
tubes, under a N2 atmosphere, in order to avoid oxidation process during heating. The tubes 
were heated at a constant temperature (160 ºC). 
 Samples of COM were analyzed at the following times: 0, 30, 60, 120, 180, 240, 300, 
360, 420, 480, 540, 600, 1800, 3600 and 5040 minutes (83 h). COMEX, TAB1 and TAB2 were 
sampled at nine pre-established times (0, 5, 10, 15, 20, 30, 45, 60 and 120 minutes).  
2.6. Chemometrics and graphics software 
The computer routines involving spectral data manipulation and the MCR-ALS 
algorithms were run in Matlab R2010a (Mathworks, Natick, USA). MCR-ALS Toolbox 1.0 
was employed as interface for als2004 routine, all routines were available at 
https://mcrals.wordpress.com/download/. 
MCR-ALS is based on the assumption of raw data matrix (D) from could be 
deconvoluted following the Lambert-Beer’s law. MCR-ALS is able to obtain the spectral (S) 
and concentration (C) contributions of the pure species of involved in process from raw spectral 
data obtained through time; D = C·ST + E, where E is the matrix of error associated to model 
fitting or the instrumental noise. 
MCR-ALS solves the equation, employing an alternating least squares algorithm which 
iteratively C and ST matrices, which optimally fit the experimental D. This optimization is 
carried out for a number of components established a priori, and using initial estimates of them. 
 Graphics and statistical data analyses were performed using OriginPro 8 SR0 
(Originlab Corporation, Northhampton, USA).  
3. Results and discussion 
 
3.1. Characterization of MFA pure polymorphs and commercial form 
 
The polymorphs of MFA (Form I and Form II) were obtained as previously reported [19] 













(Figure S2), melting point determination and DSC. The obtained results were in full agreement 
with the literature [24, 25, 26].  
The samples of the pure forms of MFA were characterized using DSC determinations and 
observations are detailed below. COM and Form I exhibited similar behavior (a transformation 
followed by a fusion) where it showed two endothermic peaks at 175 and 238 ºC, corresponding 
to Form I-Form II transition and Form II melting point, respectively. Form II showed only one 
endothermic peak corresponding to its melting point at 233 ºC. The results obtained were in 
agree with literature [19,27].  
 MIR spectra of MFA polymorphs (Figure 2) was divided in 3 main regions for its further 
analysis, 3500-1800 cm-1, 1800-1500 cm-1 and fingerprint region (1500-750 cm-1). MFA 
presented bands related to NH stretch at 3311 and 3347 cm-1, for in Form I and Form II 
respectively, in agree with previously published data [28]. 
 The second region (1800-1500 cm-1) showed the signals associated with carbonyl and 
benzene ring stretching vibrations. The carbonyl stretch is observed at 1643 cm-1 for both 
polymorphs, while the bands at 1593, 1570 and 1508 cm-1 in Form I and 1564 cm-1 in Form II 
were attributed to benzene-ring stretching and in-plane NH deformation. Finally, examination 
of the fingerprint region revealed vibrations associated with in-plane CH or ring deformation, 
represented by the bands in 1450-1200 cm-1 region. The out-of-plane CH deformations were 
found in 960-800 cm-1 range and 885-820 cm-1, for Form I and Form II respectively. The bands 
at 752-744 cm-1 (Form I) and 742 cm-1 (Form II) were assigned to ring deformation coupled 
with CO2 wagging. COM showed the same peak position and intensity of Form I in MIR.  
 The observations listed above for MIR and DSC, together complementary analysis (see 
supplementary section for NIR and Microscopy analysis), allows to conclude that crystalline 























































Figure 2. MIR Spectra for MFA polymorphs, Form II (A), Form I (B) and COM (C). 
 
 
3.2. Monitoring polymorphism behavior of MFA in formulated products   
     
 
 In order to reveal the influence of excipient mixture in a plausible polymorphic 
transformation, several samples of MFA were stressed and monitored using MIR spectroscopy.  
 As first step, the polymorphic transformation of COM submitted to thermal treatment 
(Section 2.5) was assessed in order to take into account behavior of pure MFA under 
experimental conditions. The thus obtained aliquots were measured in the range 3800–600 cm−1 
using an ATR accessory. Figure 3 shows the evolution of MIR spectra obtained for the COM 
samples submitted to treatment. A double peak was observed in the region between 3282 and 
3360 cm-1 after 6 hours of heating, which corresponds to the displacement of the stretch band 
of the -NH group, due to the conversion from Form I to II. Other changes in could be visualized 
among 1593-1492 due to benzene ring stretching, 1469-1402 for C-H or ring deformation, 
1327-1230 for Anti-symmetric CH3 and CH3’ stretching, 958-819 for Out-of-plane  CH 
deformation and at 775-742 for ring deformation and CO2 wagging (Table S1). The maximum 
polymorphic transformation was observed at 84 hours, but not complete transformation was 















Figure 3.  Surface image of the MIR spectra obtained during the thermal treatment of COM. 
In order to determine the possible influence of the excipients in the conversion of Form 
I to Form II, the physical mixtures (COMEX) containing COM and excipient matrix and 
commercial tablets (TAB1 and TAB2), were analyzed following the same strategy. 
Figure 4 shows the overall phenomena of conversion in COMEX, TAB1 and TAB2 
samples, qualitative changes can be visualized using naked eye, for example stretch band of the 
-NH (from 3282 to 3360 cm-1). However, excipients, especially carbohydrates [29] that show 
MIR absorption on the entire spectral range, interfere quantitative analysis. Thus chemometrics 
treatment of spectroscopic data arise as a plausible solution to obtain concentration profiles, 
kinetic curves, and pure spectra of polymorph. MCR-ALS emerges as the best choice, since it 
is especially suited to deal with time-evolving phenomena. MCR-ALS, is able to obtain, the 
spectral and concentration contributions of the pure species of involved in process from raw 
spectral data obtained through time. MCR-ALS is based on the assumption of raw data matrix 
from could be deconvoluted following the Lambert-Beer’s law.  
Additionally, MCR-ALS is a widespread chemometrics tool available as validated 
toolbox for R (https://cran.r-project.org/web/packages/ALS/index.html) and Matlab 
(https://mcrals.wordpress.com/download/), and it has a version in Unscrambler Software 
(https://www.camo.com/resources/multivariate-curve-resolution.html), especially suited to 
work into industry environment. Moreover, MCR is proposed as PAT tool to monitoring 
different unitary operations in pharmaceutics production coupled to Raman, MIR,  NIR and UV 













increase the guarantee that product quality is achieved consistently, and that product is 




















































































Figure 4.  Selected MIR spectra obtained during the thermal treatment of COMEX (A), TAB1 
(B) and TAB2 (C). 
Thus, MIR data obtained for the experiments (COMEX, TAB1 and TAB2) were 
arranged as matrices, time (0, 5, 10, 15, 20, 30, 45, 60 and 120 minutes) × wavenumber (3600-
600 cm-1), and analyzed using the MCR-ALS algorithm. COM samples were also analyzed in 
the same way in order to obtain comparable data for further analysis. 
Therefore, the algorithm was initialized selecting the spectra of Form I, Form II and 
excipient matrix. In order to confer physical sense to the results, data were analyzed using "non-
negativity" restriction in spectral mode and "non-negativity" and "unimodality" restrictions for 
the concentrations. The “closure condition” of the concentration values was applied among 
Form I and Form II of MFA (indicating that the sum of the abundance of species studied is 
equal to 100%). This restriction was applied after assuming that no decomposition takes place 
during the process being studied and that, therefore, there is no change in the total number of 
moles of MFA along the whole operation. 
The so obtained “pure” spectra were used to establish the identity of the species involved 
in the process. A comparison between the reference spectra of Form I and Form II and “pure” 
spectra provided by the MCR-ALS algorithm for COM, COMEX and commercial tablets 






































































Figure 5. Comparison between reference spectra (···) and MCR-ALS spectra (-) involved in 
polymorphic conversion of MFA in COM, COMEX, TAB1 and TAB2 for Form I (A) and Form 
II (B). 
Figure 6A shows the concentration profiles of Form I and Form II obtained from COM, 
as expected no intensity was found in the excipient vector form COM samples. At 7 h after 















Figure 6. MCR-ALS profiles obtained for thermal processing of COM (A), COMEX (B) TAB1 
(C) and TAB2 samples (D). Abundance of Form I (-■-) and Form II (-●-). 
 
When COMEX samples were studied (Figure 6B), the conversion process results 
accelerated in comparison to COM by a reduction of induction time and an increase of 













in pure polymorphs (Figure 5 A and B), but complete transformation to Form II was observed 
at 60 minutes. Excipient concentration profile and spectral vector showed no variation (Figure 
S3 and S4) along the experimented confirming no chemical interaction exists among MFA and 
excipients matrix. 
When commercial tablets were analyzed (Figure 6 C and D) the transformation started 
within first 10 minutes, reaching a 50% of Form II at 15 minutes. The complete polymorphic 
transformation was observed after 30 minutes, showing a slight acceleration of transformation 
process, in comparison to COMEX, due to higher interactions of MFA and excipients gained 
during manufacture. As in the case of COMEX excipients concertation profile and spectral 
vector (see supplementary material, Figure S3 and S4). 
 
Figure 7. Decay curves for Form I abundance obtained during thermal treatment of COM (■), 
COMEX (●), TAB1 (▲) and TAB2 (♦).  
 
In the case of commercial tablets (Figure 6 C and D), the MCR-concentration profiles 
evidenced the initial composition is not pure Form I, but around 90%, showing a possible 













storage. Both TAB1 and TAB2 exhibited comparable behavior, where the total transformation 
to Form II was achieved about 20 and 30 minutes for powdered (TAB1, Figure 6C), and sliced 
tablets (TAB2, Figure 6D), respectively.  
In order to analyze the kinetic behavior of polymorphic conversion of MFA, kinetics 
curves of Form I decay were constructed (Figure 7), and the experimental equations were 
calculated for its analytical comparison (Table 1). As expected, COM showed the higher 
induction time to start the transformation and therefore the lowest value of k, in agreement with 
the observation listed above. The greater conversion rate observed in the commercial tablets 
(TAB1 and TAB2) in comparison with the COMEX (physical mixture) can be explained by the 
absence of induction times in the first ones and higher kinetics constants. This observation 
allows us to infer formulated products hold higher contact among MFA and excipients. This 
higher contact, maybe obtained during granulation process, maximizes the physical MFA-
excipient interaction. 
On the other hand, the faster transformation of TAB1 (the highest k=0.03018 min
-1) 
could be explained due to its small and homogeneous particle size in comparison to TAB2, 
which improve to heat transference sample-container.  
Table 1. Equation parameters for first order exponential decay of Form I in thermal stressed 
samples.  
A= ao × e
-k (t-to) ao k 
to 
(min) 
COM 100 0.0027 180 
COMEX 100 0.026 8 
TAB1 90 0.3018 0 
TAB2 90 0.0921 0 
 
Finally, the thermal behavior of commercial tablets was also analyzed by DSC, in order 
to correlate the results obtained by MCR-ALS. The DSC thermograms are presented in Figure 
8. As described in section 3.1, COM showed two endothermic peaks at 175 and 238 ºC, 
corresponding to the transition of Form I to Form II and the melting point of as Form II, 
respectively. TAB1 also showed two endothermic peaks similar to those evidenced by COM. 









































Figure 8. DSC thermograms obtained for COM (-) and TAB1 (--). 
The heat for this transformation became almost imperceptible in comparison to the 
phenomena observed for COM. This change in the transition temperature and peak area 
suggests the presence of excipients in the formulated product interacts with MFA decreasing 
temperature and energy necessary to the crystal conversion. 
It should be noted that although a possible interaction between API and excipients could 
be supposed from the changes evidenced in the DSC thermograms (shape or area of the peaks), 
only the use of MIR spectroscopy coupled to MCR-ALS provides qualitative and quantitative 
information of the phenomenon, evidencing about the nature of such interactions. 
 
4. Conclusions 
In the present work, a smart approach based on thermal stress, MIR monitoring, MCR-
ALS algorithm and kinetic analysis was developed to explore API-excipients interactions which 
exhibit polymorphism.  MFA as drug substance, physical mixtures and commercial tablets were 
thermally stressed and analyzed in order to unveil changes in the nature of enantiotropic 
conversion of API. The proposed MIR/MCR-ALS approach allowed to determine the influence 
of excipients in the conversion process (Form I to Form II), and the kinetic studies allowed to 
infer changes of the process and involved activation energies. 
The MCR-ALS concentration profiles revealed commercial API (Form I) underwent a 













occurs in short time due to MFA-excipients physical interactions. TAB1 and TAB2 showed a 
very fast transformation of Form I to Form II, being TAB2 slightly faster, due to a better heat 
transference. Additionally, TAB1 and TAB2 MCR-analysis revealed a polymorphic change 
likely occurred during the manufacture or storage of tablets.  Change in kinetics curves 
(induction time and kinetic constant) for COM, COMEX, TAB1 and TAB2 carried out from so 
obtained MCR-concentration profiles showed a marked fall in activation energy reinforcing the 
idea of API-excipient physical interaction. 
Therefore, the developed approach, based on thermal stress, MIR/MCR-ALS resolution, 
the so obtained spectra analysis and kinetic calculations should be considered as a suitable 
strategy to reveal potentially incompatible excipients and unstable conditions from the point of 
view of polymorphism; thus improving QbD of a new product. 
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